Sodertalje, Sweden

Tord Inghardt


 

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2018-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Tord Inghardt: Innovator in Antibody Development

Introduction

Tord Inghardt is a notable inventor based in Södertälje, Sweden. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies. With a total of 5 patents to his name, Inghardt's work has the potential to impact medical treatments significantly.

Latest Patents

One of Inghardt's latest patents focuses on "Antibodies to ticagrelor and methods of use." This patent provides a comprehensive disclosure of antibodies and antigen-binding fragments that specifically bind to ticagrelor and its metabolites. The patent also outlines various compositions that include these antibodies, nucleic acid molecules encoding them, and methods for treating patients through the administration of these antibodies. This innovative approach could lead to improved therapeutic options for patients requiring ticagrelor treatment.

Career Highlights

Inghardt is currently associated with MedImmune Limited, a prominent company in the biopharmaceutical sector. His work at MedImmune has allowed him to explore and develop cutting-edge solutions in antibody technology. His contributions have been instrumental in advancing the understanding and application of therapeutic antibodies.

Collaborations

Inghardt has collaborated with several talented individuals in his field, including Sven Nylander and Mark Penney. These collaborations have fostered a productive environment for innovation and research, leading to significant advancements in antibody development.

Conclusion

Tord Inghardt's work in the field of antibody development exemplifies the impact of innovative thinking in biotechnology. His patents and collaborations highlight his commitment to advancing medical science and improving patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…